Medincell SA (MEB.BE)
| Previous close | 12.42 |
| Open | 12.48 |
| Bid | 12.46 x N/A |
| Ask | 12.90 x N/A |
| Day's range | 12.36 - 12.68 |
| 52-week range | 5.42 - 12.86 |
| Volume | |
| Avg. volume | 15 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireMedincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
MONTPELLIER, France, April 16, 2024--Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications. Medincell will use its commercial-stage long-acting injectable technology platform to formulate innovative therapies. Medincell will conduct formulation activities and preclinical studies, including supportive CMC work to advance candidates into clinical trials. AbbVie will financ
Business WireUnitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
MONTPELLIER, France, April 08, 2024--Regulatory News: Global health agency Unitaid has awarded Medincell (Paris:MEDCL) an extension grant of up to US$ 6 million over three years to fund the clinical phase 1 activities of long-acting injectable mdc-STM. If proven safe, effective, and acceptable, mdc-STM could have a significant impact on transmission of malaria among vulnerable populations in high-transmission areas.
Business WireMedinCell to Present at the 23rd Annual Needham Virtual Healthcare Conference
MONTPELLIER, France, March 27, 2024--Regulatory News: MedinCell (Paris:MEDCL) has recently reached the commercial stage with the market launch by Teva of UZEDY™ for the treatment of schizophrenia. UZEDY is the first innovative product based on MedinCell’s long-acting injectable (LAI) BEPO® technology approved by US FDA.
